$46 Million Genetic Medicines Hub Established
The University of Oxford and Boston Children’s Hospital have been selected to establish a new Genetic Medicines Hub with a $46 million multi-year commitment.
This initiative forms one of six research hubs within the Aligning Research to Impact Autism ecosystem. The collaboration also includes The Jackson Laboratory and N=1 Collaborative to develop a scalable platform for antisense oligonucleotide therapies.
Targeting Neurodevelopmental Disorders Through Platform Design
Translating genetic discoveries into therapeutic strategies is difficult despite rapid advances in sequencing. The Hub will initially focus on genes associated with neurodevelopmental disorders, including ARID1B, CHD2, GRIN2B, RNU4-2, SCN2A, and SLC6A1.
Rather than pursuing one condition at a time, the team will establish systematic methods to design and test antisense oligonucleotides across multiple targets. These short, synthetic molecules interact with RNA to modify gene expression in the central nervous system.
Pairing Genomic and Computational Tools to Develop Genetic Medicines
The program pairs high-throughput laboratory systems with novel screening approaches to assess biological impact at the protein level. Stephan Sanders, Professor of Pediatric Neurogenetics at the University of Oxford, stated, “This program represents a step change in how we approach developing genetic medicines.”
AI-informed design tools will optimize candidate molecules while integrated data platforms enable the sharing of results and protocols. Tim Yu, Associate Professor of Pediatrics at Boston Children’s Hospital, stated, “By uniting world-class teams and building a shared, transparent blueprint for ASO innovation, we aim to make that bottleneck disappear.”
Building Open Resources for Rare Disease Research
The initiative relies on contributions from multiple institutions to overcome historical data barriers in rare disease research. Cat Lutz, Vice President of the Rare Disease Translational Center at The Jackson Laboratory, stated, “For rare disease patients, the biggest barrier has never been scientific ambition, it’s been data.”
Nicole Nolen, Executive Director of N=1 Collaborative, stated, “Reaching more patients requires more than advancing individual programs – it requires a field that learns together.”
Frequently Asked Questions About the Genetic Medicines Hub
What specific genes are targeted by the new hub?
The program initially focuses on ARID1B, CHD2, GRIN2B, RNU4-2, SCN2A, and SLC6A1.
Which institutions lead the $46 million initiative?
The University of Oxford and Boston Children’s Hospital lead the collaboration alongside The Jackson Laboratory and N=1 Collaborative.
What type of therapies is the hub developing?
The facility is developing antisense oligonucleotide therapies designed to interact with RNA and modify gene expression for neurodevelopmental disorders.
Keep reading